During the ongoing SARS-CoV-2 pandemic, the Hepatology community remains deeply concerned about acute liver injury developing in healthy individuals and patients with chronic liver disease/cirrhosis. To study the spectrum of Liver Injury due to SARS-CoV-2 infection, the APASL initiated the ‘APCOLIS’ study, wherein the data was provided of such patients, including the natural course, effect of different drugs and therapies on liver functions and outcome. We want to thank you for your continued support and active participation. We were able to collect the data of 408 patients till the beginning of April. The manuscript based on this data has been submitted and is under review.
To our delight, we are regularly getting new cases from a large number of investigators and colleagues across Asia. In view of the on-going enthusiasm, we have decided to open the study portal for enrolment at present.
If you have any case of SARS-CoV-2 infection with liver injury, with or without underlying chronic liver disease/cirrhosis/decompensated cirrhosis/HCC; please do upload the cases using the link below,
Each patient data needs to be filled in the monkey survey separately, and would take just about 5 minutes.
The manuscript policy will be as per international norms, subject to your contribution.
Do join the “APCOLIS STUDY” of APASL (Clinical Trial identifier-NCT 04345640)https://www.surveymonkey.com/r/covid-liver .
Dr. Shiv. K.Sarin, M.D., D.MOn behalf of APASL